The Latest
-
Justin Sullivan via Getty Images
And just like that... pharma’s breakups reveal pain points in cancer R&D
Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.
-
Stock via Getty Images
The biggest Big Pharma losers in the first half of 2025
What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.
-
Andrew Harnik via Getty Images
MAHA leaders may take aim at pharma DTC advertising
RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.
-
Stock via Getty Images
Q&AIn cell therapy, cost is a hot issue. The industry might need a cold solution.
The logistical linchpin of cryopreservation could make a challenging space more accessible.
-
Mario Tama / Getty via Getty Images
Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market
Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole.
-
Stock via Getty Images
Biopharma layoffs rise as drugmakers tighten belts and reorganize
Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.
-
Permission granted by Merck KGaA
Merck KGaA ventures into new territory in the US
How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.
-
Alex Wong via Getty Images
With scrapped mRNA funding, a vaccine maker finds a silver lining
While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.
-
Anna Moneymaker via Getty Images
With FDA PreCheck, drugmakers may get a manufacturing boost
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
-
Stock via Getty Images
Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise
Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.
-
Scott Olson via Getty Images
3 ways the GLP-1 market has changed shape this year
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
-
Stock via Getty Images
Are stem cell therapies ready for pharma’s prime time?
Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.
-
Stock via Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
-
Permission granted by AstraZeneca
Q&AInside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
-
Andrew Harnik via Getty Images
PBM reform was dropped from Trump’s spending bill. It could have saved billions.
The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.
-
Chip Somodevilla / Staff via Getty Images
Let’s make a deal? Big Pharma execs express varying views on their M&A future
Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.
-
Permission granted by Vertex Pharmaceuticals
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
-
stock via Getty Images
Drugmakers score policy win in a prolonged fight against 340B
A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.
-
Courtesy of Merck & Co.
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
-
Permission granted by Novo Nordisk
C-suite shuffles ripple through pharma
Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.
-
Permission granted by Roche
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
-
Retrieved from Vinay Prasad on May 08, 2025
Dr. Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.
-
Stock via Getty Images
Biotech investing is down, but some VC firms are bucking the trend
Discipline is the name of the game after a glut of over-investing burst the biotech bubble.
-
Permission granted by Merck & Co.
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
-
E+ via Getty Images
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
